{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:29:54Z","timestamp":1790026194937,"version":"4.0.1"},"reference-count":102,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":10728,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1982,9,10]]},"abstract":"<jats:p>Alprazolam, a triazolobenzodiazepine, is the first of this new class of benzodiazepine drugs to be marketed in the United States and Canada. It achieves peak serum levels in 0.7 to 2.1 hours and has a serum half\u2010life of 12 to 15 hours. When given in the recommended daily dosage of 0.5 to 4.0 mg, it is as effective as diazepam and chlordiazepoxide as an anxiolytic agent. Its currently approved indication is for the treatment of anxiety disorders and symptoms of anxiety, including anxiety associated with depression. Although currently not approved for the treatment of depressive disorders, studies published to date have demonstrated that alprazolam compares favorably with standard tricyclic antidepressants. Also undergoing investigation is the potential role of alprazolam in the treatment of panic disorders. Alprazolam has been used in elderly patients with beneficial results and a low frequency of adverse reactions. Its primary side effect, drowsiness, is less than that produced by diazepam at comparable doses. Data on toxicity, tolerance, and withdrawal profile are limited, but alprazolam seems to be at least comparable to other benzodiazepines. Drug interaction data are also limited, and care should be exercised when prescribing alprazolam for patients taking other psychotropic drugs because of potential additive depressant effects.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1982.tb03191.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T13:52:54Z","timestamp":1450273974000},"page":"243-253","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Alprazolam: Pharmacokinetics, Clinical Efficacy, and Mechanism of Action"],"prefix":"10.1002","volume":"2","author":[{"given":"Jan A.","family":"Fawcett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Kravitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"S123","article-title":"New benzodiazepine analogs. Synthesis and CNS activity","volume":"3","author":"Moffett RB.","year":"1976","journal-title":"J Heterocyclic Chem."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(01)98659-9"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.21.489"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.21.497"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00197a021"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(01)87414-1"},{"key":"e_1_2_1_8_2","first-page":"285","volume-title":"The benzodiazepines","author":"Rudzik AD","year":"1973"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.2590090307"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.21.1619"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.21.2382"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1976.001.12.300787"},{"key":"e_1_2_1_13_2","first-page":"505","article-title":"Progress in the field of drug development","volume":"31","author":"Horig C.","year":"1976","journal-title":"Die Pharmazi."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.5570130340"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00230a016"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00230a017"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.25.2584"},{"key":"e_1_2_1_18_2","first-page":"229","article-title":"The benzodiazepine story","volume":"22","author":"Sternbach LH.","year":"1978","journal-title":"Prog Drug Res."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00204a008"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00210a022"},{"key":"e_1_2_1_21_2","first-page":"129","article-title":"Animal techniques for evaluating benzodiazepine drugs","volume":"1","author":"Deangelis L.","year":"1979","journal-title":"Methods Findings Exp Clin Pharmacol."},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)83847-9"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/00032717908055716"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00197a021"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(80)90355-X"},{"key":"e_1_2_1_26_2","first-page":"279","article-title":"Disposition of 14C\u2010alprazolam, a new anxiolytic\u2010antidepressant, in man","volume":"22","author":"Eberts FS","year":"1980","journal-title":"Pharmacologist."},{"key":"e_1_2_1_27_2","first-page":"633","article-title":"Alprazolam (Xanax, The Upjohn Company)","volume":"15","author":"Evans RL.","year":"1981","journal-title":"Drug Intell Clin Pharm."},{"key":"e_1_2_1_28_2","volume-title":"Pharmacokinetic profile for alprazolam (Xanax) tablets","author":"Wallingford DM","year":"1981"},{"key":"e_1_2_1_29_2","first-page":"267","article-title":"Alprazolam kinetics in the elderly: relation to antipyrine disposition (abstract)","volume":"29","author":"Moschitto LJ","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"e_1_2_1_30_2","volume-title":"Clinical, pharmacological and toxicological studies on alprazolam (U\u201031,889)","author":"Rudzik AD","year":"1980"},{"key":"e_1_2_1_31_2","volume-title":"Xanax information piece","author":"Raskin R.","year":"1981"},{"key":"e_1_2_1_32_2","volume-title":"Effect of food on the bioavailability of Xanax (alprazolam) following a single oral 1.0 mg dose","author":"Smith RB","year":"1981"},{"key":"e_1_2_1_33_2","first-page":"41","article-title":"Alprazolam (Xanax)","volume":"24","year":"1982","journal-title":"Med Lett Drugs Ther."},{"key":"e_1_2_1_34_2","article-title":"Alprazolam kinetics in the elderly: relation to antipyrine disposition","author":"Greenblatt DJ","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_35_2","first-page":"37","article-title":"Alprazolam: a new benzodiazepine anxiolytic","volume":"16","author":"Ayd FJ","year":"1981","journal-title":"Int Drug Ther Newsletter."},{"key":"e_1_2_1_36_2","first-page":"603","article-title":"Anxiolytic effects of a new triazolobenzodiazepine, U\u201031, 889","volume":"5","author":"Itil TM","year":"1973","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1094352"},{"key":"e_1_2_1_38_2","unstructured":"LysaghtR RothT KramerMet al.A dose\u2010response study of the acute effects of diazepam and alprazolam on human sleep. Abstracts of the 17th Annual Meeting Association for Psychophysiological Study of Sleep Houston Texas April 27May 1 1977:146."},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432435"},{"key":"e_1_2_1_40_2","first-page":"1010","article-title":"Pilot open\u2010label study on U\u201031,889 in anxious inpatients","volume":"16","author":"Fabre LF","year":"1974","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_41_2","first-page":"347","article-title":"Multicenter double\u2010blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients","volume":"42","author":"Cohn JB.","year":"1981","journal-title":"J Clin Psychiatry."},{"key":"e_1_2_1_42_2","first-page":"223","article-title":"Alprazolam efficacy in anxiety (abstract)","volume":"25","author":"Fabre LF","year":"1979","journal-title":"Clin Pharmacol Ther."},{"key":"e_1_2_1_43_2","first-page":"519","article-title":"A double\u2010blind study comparing the efficacy and safety of alprazolam with diazepam and placebo in anxious outpatients","volume":"25","author":"Fabre LF","year":"1979","journal-title":"Curr Thr Res."},{"key":"e_1_2_1_44_2","unstructured":"ItohH TakahashiR MiuraS.Alprazolam a new type anxiolytic in neurotic patients \u2014 a pilot study. Abstracts of the 12th Annual Collegium International Neuro\u2010Psychopharmacologicum Goteborg Sweden June 2226 1980:187."},{"key":"e_1_2_1_45_2","unstructured":"RickelsK.Alprazolam in anxiety and depression. Abstracts of the 12th Annual Collegium International Neuro\u2010Psychopharmacologicum Goteborg Sweden June 2226 1980:297."},{"key":"e_1_2_1_46_2","first-page":"245","article-title":"Alprazolam compared to diazepam and placebo in the treatment of anxiety","volume":"41","author":"Aden GC","year":"1980","journal-title":"J Clin Psychiatry."},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800207"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1980.tb01689.x"},{"key":"e_1_2_1_49_2","first-page":"40","article-title":"Recent advances in anxiolytic therapy","volume":"42","author":"Rickels K.","year":"1981","journal-title":"J Clin Psychiatry."},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006057700500104"},{"key":"e_1_2_1_51_2","first-page":"169","article-title":"Double\u2010blind comparison of alprazolam and diazepam for subchronic withdrawal from alcohol","volume":"42","author":"Kolin IS","year":"1981","journal-title":"J Clin Psychiatry."},{"key":"e_1_2_1_52_2","first-page":"430","article-title":"A double\u2010blind comparison of the anxiolytic efficacy of alprazolam and chlordiazepoxide hydrochloride in the chronic withdrawal period from alcohol","volume":"26","author":"McLendon DM","year":"1979","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_53_2","first-page":"447","article-title":"A double\u2010blind comparison of the efficacy of alprazolam, chlordiazepoxide hydrochloride and placebo in the chronic withdrawal period from alcohol","volume":"28","author":"McLendon DM","year":"1980","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_54_2","first-page":"524","volume-title":"Diagnosis and drug treatment of psychiatric disorders: adults and children","author":"Klein DF","year":"1980"},{"key":"e_1_2_1_55_2","first-page":"539","volume-title":"Diagnosis and drug treatment of psychiatric disorders: adults and children","author":"Klein DF","year":"1980"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207153070304"},{"key":"e_1_2_1_57_2","first-page":"1","article-title":"Treating panic attacks","volume":"5","author":"Gelenberg AJ","year":"1982","journal-title":"Massachusetts General Hospital Newsletter Biological Therapies in Psychiatry."},{"key":"e_1_2_1_58_2","volume-title":"Diagnostic and statistical manual of mental disorders (DSM\u2010III)","year":"1980"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-197312000-00006"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770350085008"},{"key":"e_1_2_1_61_2","first-page":"30","article-title":"Drug treatment in depressive illness","volume":"31","author":"Rickels K","year":"1970","journal-title":"Dis Nerv Syst."},{"issue":"11","key":"e_1_2_1_62_2","first-page":"39","article-title":"Treatment of anxiety and depression. A comparative trial of amitriptyline (Laroxyl) and diazepam (Valium)","volume":"174","author":"Hare MK.","journal-title":"Clin Trials J."},{"key":"e_1_2_1_63_2","first-page":"575","article-title":"When is a tranquilizer an antidepressant?","volume":"13","author":"Claghorn J","year":"1971","journal-title":"Clin Ther Res."},{"key":"e_1_2_1_64_2","first-page":"22","article-title":"The treatment of anxiety\/depressive states","volume":"8","author":"Sim M","year":"1971","journal-title":"Clin Trials J."},{"key":"e_1_2_1_65_2","first-page":"268","volume-title":"Diagnosis and drug treatment of psychiatric disorders: adults and children","author":"Klein DF","year":"1980"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01834.x"},{"key":"e_1_2_1_67_2","first-page":"201","article-title":"Controlled comparison of bromazepam, amitriptyline, and placebo in anxiety\u2010depression","volume":"38","author":"Shammas E.","year":"1977","journal-title":"Dis Nerv System."},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.117.541.667"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760070050008"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.131.2.191"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426739"},{"key":"e_1_2_1_72_2","first-page":"661","article-title":"Pilot open\u2010label study with alprazolam (U\u201031,889) in outpatients with neurotic depression","volume":"19","author":"Fabre LF.","year":"1976","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_73_2","first-page":"379","volume-title":"The benzodiazepines","author":"Cassano GB","year":"1973"},{"key":"e_1_2_1_74_2","volume-title":"Double\u2010blind efficacy and safety study comparing alprazolam (U\u201031,889), diazepam and placebo in the treatment of primary depression (Protocol 6235, Investigator: Samuel I. Feurst, M.D.)","author":"Pollock DR","year":"1979"},{"key":"e_1_2_1_75_2","first-page":"542A","article-title":"A double\u2010blind comparison of alprazolam, imipramine, and placebo in primary depression (abstract)","volume":"27","author":"Fabre LF","year":"1979","journal-title":"Clin Res"},{"key":"e_1_2_1_76_2","first-page":"474","article-title":"A double\u2010blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression","volume":"27","author":"Fabre LF","year":"1980","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_77_2","first-page":"649","article-title":"A double\u2010blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression (errata)","volume":"27","author":"Fabre LF","year":"1980","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_78_2","first-page":"196","volume-title":"Modern problems of pharmacopsychiatry","author":"Feighner JP.","year":"1982"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1972.01750190059011"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.01750330049009"},{"key":"e_1_2_1_83_2","unstructured":"StrawRN LinetOI RudzikAD.Summary of clinical studies on alprazolam. Unpublished report on fle at The Upjohn Company Kalamazoo MI;1980."},{"key":"e_1_2_1_84_2","first-page":"419","article-title":"Cardiopulmonary and amnestic effects of alprazolam \u2014 a new benzodiazepine derivative (abstract)","author":"Hess WH","year":"1977","journal-title":"Proc Am Soc Anesthesiol."},{"key":"e_1_2_1_85_2","first-page":"270","article-title":"The cardiopulmonary effects of alprazolam \u2014 a new benzodiazepine derivative","volume":"74","author":"Boyd EL","year":"1978","journal-title":"W Va Med J."},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03300130045021"},{"key":"e_1_2_1_87_2","first-page":"858","article-title":"Benzodiazepines and neurotransmitters","volume":"30","author":"Costa E.","year":"1980","journal-title":"Arzneimittel-forsch."},{"key":"e_1_2_1_88_2","first-page":"1359","volume-title":"Psychopharmacology: a generation of progress","author":"Haefely WE.","year":"1978"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(78)90364-8"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/287651a0"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.3.1939"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.918669"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.9.3805"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6101294"},{"key":"e_1_2_1_95_2","volume-title":"Some pharmacological studies with alprazolam (progress report)","author":"Pandey GN","year":"1982"},{"key":"e_1_2_1_96_2","first-page":"83","volume-title":"Pharmacology of sleep","author":"Kay DC","year":"1976"},{"key":"e_1_2_1_97_2","first-page":"225","volume-title":"Pharmacology of sleep","author":"Itil TM.","year":"1976"},{"key":"e_1_2_1_98_2","first-page":"159","article-title":"REM latency: a psychobiological marker for primary depressive disease","volume":"11","author":"Kupfer D.","year":"1976","journal-title":"Biol Psychiatry."},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.138.4.429"},{"key":"e_1_2_1_100_2","first-page":"388","article-title":"Pharmacology: new antidepressants","volume":"10","author":"Feighner J.","year":"1980","journal-title":"Psych Ann."},{"key":"e_1_2_1_101_2","first-page":"23","article-title":"Clinical efficacy of the newer antidepressants","volume":"1","author":"Feighner J.","year":"1981","journal-title":"J Clin Pharmacol."},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.137.5.545"},{"key":"e_1_2_1_103_2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.1981.03310400044029","article-title":"Diagnosis of depression in the 1980s","volume":"245","author":"Gold MS","year":"1981","journal-title":"JAMA."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1982.tb03191.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1982.tb03191.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1982.tb03191.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:09Z","timestamp":1761042249000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1982.tb03191.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,9,10]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1982,9,10]]}},"alternative-id":["10.1002\/j.1875-9114.1982.tb03191.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1982.tb03191.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,9,10]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}